Leukemic stem cells (LSCs) and stemness signatures contribute to minimal residual disease in patients with acute myeloid ...

In the early days of the second Trump administration, what will happen to various government science agencies is not yet ...

Biopharma companies secured $5.91 billion across 93 transactions in January 2025, a continuing upward swing from $4.69 ...

This current administration is like nothing that we've seen before,” said a managing partner of a global venture capital firm ...

Melanoma is the most aggressive form of skin cancer and often spreads to the brain. Though immunotherapy has greatly improved ...

For the pharmaceutical industry caught in the crosshairs of a potential trade war, the consequences of U.S. tariffs on China ...

The development of an effective HIV vaccine remains an urgent public health need due to the high genetic variability and rapid mutation rates of the virus, which limit the generation of broadly ...

Cyclin-dependent kinases 4 and 6 (CDK4/6) are crucial cell cycle regulators and have become significant targets in breast cancer therapy. Current CDK4/6 inhibitors, while effective, often come with ...

Eli Lilly and Co.’s end last year to its PI3Kα inhibitor program didn’t mean the pharma player was giving up on the target – ...

Curently the only available blood test to tell which women are at risk of postpartum depression (PPD) is the one that ...

Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the ...

Europe has more oncology startups than the U.S., but many more U.S. companies scale up to the later growth stage. Given the ...